**ATXN7L3B Gene Description:**

The ATXN7L3B gene encodes a protein that is involved in the regulation of gene expression by influencing the activity of the SAGA (Spt-Ada-Gcn5 acetyltransferase) complex, a critical player in transcriptional regulation. Notably, ATXN7L3B interacts with ENY2, which modifies the deubiquitination activity of histones via the DUB module of the SAGA complex. This modulation can impact histone ubiquitination dynamics, particularly H2B monoubiquitination (H2Bub1), a marker associated with transcriptional elongation and gene expression regulation.

---

### 1. Associated Genes:
In addition to the genes explicitly mentioned in the summaries, ATXN7L3B may be associated with:
- **ATXN7**: Since ATXN7L3B is known to interact with ATXN7, and both are components of the SAGA complex, any changes in one may affect the functioning of the other.
- **USP22**: This deubiquitinating enzyme is part of the SAGA complex and is directly influenced by the binding dynamics in the presence or absence of ENY2 regulated by ATXN7L3B.
- **ENY2**: As a direct interactor, it plays a pivotal role in this functional relationship.
- Other genes involved in the SAGA complex or chromatin remodeling, such as histone-modifying enzymes and other associated SAGA components, might also be indirectly influenced by ATXN7L3B.

### 2. Details Related to Aging or Age-Related Diseases:
While specific studies directly linking ATXN7L3B to aging or age-related diseases are limited, proteins involved in the regulation of transcription and chromatin modifications, like those in the SAGA complex, are often implicated in cellular aging processes. Dysregulation of these pathways could potentially lead to age-related diseases, including certain cancers and neurodegenerative disorders.

- **Neurodegenerative Diseases**: Given that the ATXN7 gene is linked to spinocerebellar ataxia (SCA) type 7, alterations in ATXN7L3B's function may contribute indirectly to neurodegenerative disorders characterized by aging.
- **Cancer**: The connection of ATXN7L3B with USP22, known for its role in cancer cell proliferation and survival, suggests that it may also be involved in age-related oncogenesis.

### 3. Drug or Drug Classes Interactions:
While there are no specific drugs explicitly listed that interact with ATXN7L3B in common databases, compounds acting as histone deacetylase inhibitors (HDACi) or proteasome inhibitors may influence the pathways in which ATXN7L3B participates. These include:

- **HDAC inhibitors**: Such as vorinostat (suberoylanilide hydroxamic acid), which influences histone modification and chromatin structure.
- **Proteasome inhibitors**: Such as bortezomib, may affect the stability of proteins involved in the SAGA complex indirectly through altered ubiquitination pathways.

Specific studies or clinical trials would provide more precise information if a direct interaction was established.

### 4. Pathways and Biological Processes:
ATXN7L3B is involved in several important biological processes, including but not limited to:

- **Gene Expression Regulation**: Through its interactions with the SAGA complex.
- **Histone Modification**: Specifically influencing H2B monoubiquitination, which is critical for transcriptional regulation.
- **Cytoplasmic Sequestration**: Regulating the availability of ENY2, subsequently altering DUB activity and subcellular localization of proteins involved in chromatin dynamics.
- **Cell Cycle Regulation and Senescence**: Given the role of ubiquitination in controlling protein degradation and function, ATXN7L3B might indirectly participate in processes associated with cell cycle progression and cellular aging.

In summary, ATXN7L3B plays a crucial role in transcriptional regulation and chromatin dynamics, with potential implications in aging and age-related diseases, though specific links to drugs and detailed pathway analyses may require further research for clarification.